BI 706321 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - P2 | N=49 | Terminated | Sponsor: Boehringer Ingelheim | Trial completion date: Mar 2025 ➔ Aug 2024 | Active, not recruiting ➔ Terminated; Company decision

Trial completion date • Trial termination • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP • IL23A

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=48 | Terminated | Sponsor: Boehringer Ingelheim | Trial completion date: Oct 2025 ➔ Aug 2024 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2025 ➔ Aug 2024; Company decision

Trial completion date • Trial primary completion date • Trial termination

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - P2 | N=49 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP • IL23A

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Feb 2025 ➔ Oct 2025 | Trial primary completion date: Feb 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Boehringer Ingelheim | Phase classification: P2a ➔ P2

Phase classification • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP • IL23A

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Oct 2024 ➔ Feb 2025 | Trial primary completion date: Oct 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - P2a | N=50 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Nov 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Feb 2024 ➔ Oct 2024 | Trial primary completion date: Feb 2024 ➔ Oct 2024

Trial completion date • Trial primary completion date

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Recruiting

Enrollment open

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - P2a | N=50 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Feb 2024 ➔ Nov 2024 | Trial primary completion date: Jun 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jun 2023 ➔ Feb 2024 | Trial primary completion date: Jun 2023 ➔ Feb 2024

Trial completion date • Trial primary completion date

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - P2a | N=50 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Aug 2023 ➔ Feb 2024 | Trial primary completion date: Nov 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn’s Disease (clinicaltrials.gov) - P2a; N=50; Not yet recruiting; Sponsor: Boehringer Ingelheim

New P2a trial • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn’s Disease (clinicaltrials.gov) - P2a; N=50; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn’s Disease (clinicaltrials.gov) - P2a; N=50; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Mar 2023 ➔ Jul 2023; Trial primary completion date: Jul 2022 ➔ Nov 2022

Clinical • Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Sep 2022 ➔ Jul 2023 | Trial primary completion date: Sep 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Boehringer Ingelheim

Clinical • New P1 trial

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (clinicaltrials.gov) - P1; N=14; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (clinicaltrials.gov) - P1; N=14; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (clinicaltrials.gov) - P1; N=14; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (clinicaltrials.gov) - P1; N=14; Not yet recruiting; Sponsor: Boehringer Ingelheim

Clinical • New P1 trial

A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - P1; N=39; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - P1; N=61; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed

Clinical • Trial completion